AEON Biopharma, Inc. Class A (AEON)
AEON moved a median of -0.97% 30 minutes after news, and -0.78% by the close. How AEON actually reacts to news — the realized, point-in-time move the market made, measured across 165 labeled events over the last three years with zero look-ahead.
AEON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 150 |
| 30-min | -0.97% | 34% | 164 |
| 60-min | -1.64% | 39% | 165 |
| to close | -0.78% | 46% | 164 |
| Middle 50% of AEON reactions | -3.01% to +1.90% |
|---|---|
| Median reaction (30-min) | -0.97% |
| Measured reactions | 165 |
Half of all AEON Biopharma, Inc. Class A news events land between -3.01% and +1.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AEON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AEON's baseline. Nothing else.
Recent AEON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A AEON Biopharma, Inc. For: Oct 13 | SEC filing · Form PRE | SEC EDGAR | +3.35% | -0.48% | |
| AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | Press release | GlobeNewswire | +3.47% | -10.40% | |
| AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 | Press release | GlobeNewswire | -17.50% | -6.42% | |
| Form 8-K AEON Biopharma, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -17.50% | -6.42% | |
| AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® | Press release | GlobeNewswire | -5.64% | -6.86% | |
| AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference | Press release | GlobeNewswire | -0.49% | -4.05% | |
| AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer | Press release | GlobeNewswire | +0.40% | -1.79% | |
| AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® | Press release | GlobeNewswire | -2.88% | -13.55% | |
| AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.28% | -3.80% | |
| AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | Press release | GlobeNewswire | -1.39% | +0.65% | |
| AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | Press release | GlobeNewswire | -3.45% | +23.10% | |
| AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society | Press release | GlobeNewswire | +0.00% | -1.07% | |
| AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -7.49% | |
| AEON Biopharma Sets Annual Shareholder Meeting | Press release | GlobeNewswire | +3.10% | +7.22% | |
| AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards | Press release | GlobeNewswire | +9.95% | +4.48% | |
| AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | Press release | GlobeNewswire | +9.95% | +4.48% | |
| AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program | Press release | GlobeNewswire | -17.92% | -17.92% | |
| AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program | Press release | GlobeNewswire | — | -3.77% | |
| AEON Biopharma Appoints John Bencich as Chief Financial Officer | Press release | GlobeNewswire | +3.81% | +9.52% | |
| Form 8-K AEON Biopharma, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +3.81% | +9.52% | |
| AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting | Press release | GlobeNewswire | +0.98% | +3.92% | |
| Form EFFECT AEON Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +13.13% | |
| Form S-3 AEON Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.01% | -0.94% | |
| AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions | Press release | GlobeNewswire | +1.49% | -12.69% | |
| Form 8-K AEON Biopharma, Inc. For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | -12.69% | |
| Form 8-K AEON Biopharma, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | +2.85% | |
| Form DEF 14A AEON Biopharma, Inc. For: Dec 29 | SEC filing · Form DEF | SEC EDGAR | — | +4.85% | |
| AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | Press release | GlobeNewswire | +1.91% | -0.95% | |
| Form PRE 14A AEON Biopharma, Inc. For: Dec 19 | SEC filing · Form PRE | SEC EDGAR | +1.91% | -0.95% | |
| AEON Biopharma Announces Execution of Exchange Agreement with Daewoong | Press release | GlobeNewswire | -2.19% | +19.21% | |
| Form 8-K AEON Biopharma, Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | +19.21% | |
| Form 8-K AEON Biopharma, Inc. For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -1.65% | -7.59% | |
| AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling | Press release | GlobeNewswire | +1.04% | -10.90% | |
| AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth | Press release | GlobeNewswire | -5.18% | -4.78% | |
| Form 10-Q AEON Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.18% | -4.78% | |
| Form 8-K AEON Biopharma, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -5.18% | -4.78% | |
| Form DEFA14A AEON Biopharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -5.18% | -4.78% | |
| Form 8-K AEON Biopharma, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +2.13% | — | |
| Form 8-K AEON Biopharma, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +1.90% | +2.25% | |
| Form 10-Q AEON Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.33% | +19.67% | |
| Form 8-K AEON Biopharma, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | +19.67% | |
| Form 8-K AEON Biopharma, Inc. For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | -6.02% | |
| Form 10-K/A AEON Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.15% | -3.84% | |
| Form 10-Q/A AEON Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.15% | -3.84% | |
| Form DEFR14A AEON Biopharma, Inc. | SEC filing · Form DEFR14A | SEC EDGAR | +0.62% | +0.24% | |
| AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | Press release | GlobeNewswire | +1.12% | +6.49% | |
| Form 8-K AEON Biopharma, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -2.72% | |
| AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 | Press release | GlobeNewswire | -4.39% | -2.92% | |
| AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.10% | +6.02% | |
| Form 10-Q AEON Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.10% | +6.02% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AEON section they belong to.
Where else AEON is measured.
AEON earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AEON Biopharma, Inc. Class A's median reaction calculated?
Every labeled AEON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 165 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of AEON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AEON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.